Community Magazine
Friends and CLL Society supporters:This isn't easy.After consulting with my wife, my family, my closest friends and key supporters of the CLL Society, I decided it was best to again share details of my personal battle with CLL in a very public way.After a wonderful run of 69 months on Ibrutinib, my CLL is now officially relapsing. I am very grateful to Dr. Byrd and the team at Ohio State for their great care over the past 6 years.But it is time to move on.Very soon, I will be undergoing innovative CAR-T therapy as part of a phase I/II clinical trial.I am confident that this CAR-T trial offers me the very best chance for a long and deep remission.I will be frequently blogging and sharing all details about my CAR-T experience here. My first more detailed post that share more about my decision is already up. Please take a look, stay in touch and share your thoughts. More details will be coming soon.Independent of and prior to this big decision, we have produced a fun comic book about CAR-T. It's up on the website too.We will be bringing much more information and support about CART-T over the next few months on a new CAR-T section of the website https://cllsociety.org/car-t-and-other-cellular-therapies/.I hope others will benefit from following my CAR-T story as I begin this new adventure.Your thoughts, prayers and support are greatly appreciated.Stay strong.We are all in this together.Brian Koffmanhttp://cllsociety.orgIf you want a personal response, or just want to stay in touch, please email me at [email protected]. I have no other way of contacting. Thanks. Stay strong. After all, we are all in this together. And please visit our website: http://cllsociety.org for the latest news and information.
Author's Latest Articles
-
A Matching-Adjusted Indirect Comparison of Acalabrutinib Vs. Zanubrutinib in Relapsed Or Refractory CLL
-
My Personal Decision to Restart My CLL (chronic Lymphocytic Leukemia) Treatment
-
ASH 2022: Adverse Events from BTK Inhibitors in Clinical Trials
-
Dr. Stephan Stilgenbauer on the Evolution of CLL to Richter’s Syndrome from ASH 2022